Skip to main content
. 2021 Jan 19;12(2):66–80. doi: 10.18632/oncotarget.27868

Figure 3. ICB enhanced the anti-tumor efficacy of TA99 in B16 subcutaneous melanoma.

Figure 3

Treatment schedule of B16 melanoma bearing C57BL/6 mice with TA99 mAb alone or in combination with anti-PD1 or anti-CTLA4 (A). TA99 or ICB therapy alone resulted in modest tumor growth inhibition, which became highly significant when these therapeutic agents were combined (B). Differences in tumor growth were determined by two-way ANOVA with Bonferroni correction (n = 10 mice per group). * p < 0.05; ** p < 0.001; *** p < 0.0001. Left panel shows the comparison of different treatment with the untreated control group. Statistical significance on the right panel shows comparison with the no TA99 control group (left). At the end point, tumors treated with TA99 and anti-CTLA4 (C), and anti-PD1 (D) were collected after euthanasia and immunophenotyped by FACS analysis. Individual tumors are represented in the scatter plots and the median is shown. * p < 0.05; ** p < 0.001; *** p < 0.0001.